Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
Articles from other publishers (6)
Jing Huang, Yuntao Jia, Shusen Sun & Long Meng. (2020) Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacology and Toxicology 21:1.
Crossref
Crossref
Yan-Rong Li, Sung-Sheng Tsai, Dong-Yi Chen, Szu-Tah Chen, Jui-Hung Sun, Hung-Yu Chang, Miaw-Jene Liou & Tien-Hsing Chen. (2018) Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke. Cardiovascular Diabetology 17:1.
Crossref
Crossref
Ruben Vardanyan. 2017. Piperidine-Based Drug Discovery. Piperidine-Based Drug Discovery
127
146
.
Yanwei Li, Lin Li & Christian Hölscher. (2016) Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences 27:7, pages 689-711.
Crossref
Crossref
Shan-yao Ma, Meng-meng Ning, Qing-an Zou, Ying Feng, Yang-liang Ye, Jian-hua Shen & Ying Leng. (2016) OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition. Acta Pharmacologica Sinica 37:10, pages 1359-1369.
Crossref
Crossref
Xiaohui Bai, Youhong Niu, Jingjing Zhu, An-Qi Yang, Yan-Fen Wu & Xin-Shan Ye. (2016) A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus. Bioorganic & Medicinal Chemistry 24:6, pages 1163-1170.
Crossref
Crossref